Jianmin Pharmaceutical Group Co.,Ltd.

SHSE:600976 Stock Report

Market Cap: CN¥6.4b

Jianmin Pharmaceutical GroupLtd Future Growth

Future criteria checks 3/6

Jianmin Pharmaceutical GroupLtd is forecast to grow earnings and revenue by 22.2% and 12.3% per annum respectively. EPS is expected to grow by 22.2% per annum. Return on equity is forecast to be 21.5% in 3 years.

Key information

22.2%

Earnings growth rate

22.2%

EPS growth rate

Pharmaceuticals earnings growth18.9%
Revenue growth rate12.3%
Future return on equity21.5%
Analyst coverage

Low

Last updated22 Nov 2024

Recent future growth updates

No updates

Recent updates

Potential Upside For Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) Not Without Risk

Nov 10
Potential Upside For Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) Not Without Risk

If EPS Growth Is Important To You, Jianmin Pharmaceutical GroupLtd (SHSE:600976) Presents An Opportunity

Sep 25
If EPS Growth Is Important To You, Jianmin Pharmaceutical GroupLtd (SHSE:600976) Presents An Opportunity

Calculating The Fair Value Of Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976)

Aug 25
Calculating The Fair Value Of Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976)

The Market Doesn't Like What It Sees From Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Earnings Yet As Shares Tumble 27%

Jul 12
The Market Doesn't Like What It Sees From Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Earnings Yet As Shares Tumble 27%

We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt

Jun 30
We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt

We Ran A Stock Scan For Earnings Growth And Jianmin Pharmaceutical GroupLtd (SHSE:600976) Passed With Ease

May 21
We Ran A Stock Scan For Earnings Growth And Jianmin Pharmaceutical GroupLtd (SHSE:600976) Passed With Ease

We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings

Apr 26
We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings

Earnings and Revenue Growth Forecasts

SHSE:600976 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20265,393749N/A7401
12/31/20254,894638N/A2481
12/31/20244,446533N/A5491
9/30/20243,97742891206N/A
6/30/20244,061508156245N/A
3/31/20244,170521214284N/A
12/31/20234,213521204268N/A
9/30/20233,948508221287N/A
6/30/20233,965472131212N/A
3/31/20233,736419196270N/A
12/31/20223,641408148216N/A
9/30/20223,50336396152N/A
6/30/20223,344326203254N/A
3/31/20223,3763243788N/A
12/31/20213,299305192248N/A
9/30/20213,456279197253N/A
6/30/20213,221258130175N/A
3/31/20212,857199127175N/A
1/1/20212,45614880126N/A
9/30/20202,01314494149N/A
6/30/20202,154931483N/A
3/31/20202,164831181N/A
1/1/20202,23991574N/A
9/30/20192,40282-3235N/A
6/30/20192,19980-1241N/A
3/31/20192,183792773N/A
1/1/20192,161812164N/A
9/30/20182,188915192N/A
6/30/20182,311100N/A130N/A
3/31/20182,625102N/A93N/A
12/31/20172,71291N/A35N/A
9/30/20172,74881N/A72N/A
6/30/20172,67771N/A54N/A
3/31/20172,31559N/A41N/A
12/31/20162,36465N/A114N/A
9/30/20162,49569N/A87N/A
6/30/20162,43080N/A21N/A
3/31/20162,44983N/A2N/A
12/31/20152,28186N/A48N/A
9/30/20151,95386N/A49N/A
6/30/20151,860102N/A130N/A
3/31/20151,748114N/A107N/A
12/31/20141,753116N/A103N/A
9/30/20141,685118N/A56N/A
6/30/20141,716108N/A56N/A
3/31/20141,86798N/A89N/A
12/31/20131,99296N/A45N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600976's forecast earnings growth (22.2% per year) is above the savings rate (2.8%).

Earnings vs Market: 600976's earnings (22.2% per year) are forecast to grow slower than the CN market (25.5% per year).

High Growth Earnings: 600976's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 600976's revenue (12.3% per year) is forecast to grow slower than the CN market (13.7% per year).

High Growth Revenue: 600976's revenue (12.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 600976's Return on Equity is forecast to be high in 3 years time (21.5%)


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 16:30
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jianmin Pharmaceutical Group Co.,Ltd. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Jing QiangChina International Capital Corporation Limited
Xiaoyu QianHuatai United Securities Co., Ltd.